Oppenheimer Cuts Aduro Biotech (NASDAQ:ADRO) Stock To a “Perform” Rating

Share

Aduro Biotech (NASDAQ:ADRO) Receives a Downgrade

Shares of New York-listed Aduro Biotech (NASDAQ:ADRO) Have been downgraded by stock research analysts at Oppenheimer. Oppenheimer lowered their rating for the $1.88B market cap company to a “Perform” from their previous “Outperform” rating.

From a total of 5 analysts covering Aduro Biotech (NASDAQ:ADRO) stock, 6 rate it a ”Buy”, 0 a “Sell”, and 0 a ”Hold”. This means that 100% of the ratings are positive. The highest target price is $68 while the lowest target price is $30. The mean of all analyst targets is $45.8 with a 80.44% above today’s ($29.65) stock price. Aduro Biotech was the topic of 7 analyst reports since August 19, 2015 according to the firm StockzIntelligence Inc. Oppenheimer downgraded shares on December 1 to “Perform” rating. Oppenheimer initiated shares with “Outperform” rating and $30 target share price in a report from an October 20. Roth Capital maintained ADRO stock in a recent report from November 24 with “Buy” rating. Finally, Leerink Swann initiated the stock with “” rating in a report issued on an August 19.

Approximately 20,367 shares of stock traded hands. Aduro BioTech Inc (NASDAQ:ADRO) has risen 10.80% since April 28, 2015 and is uptrending. It has outperformed by 12.42% the S&P500.

Oppenheimer Cuts Aduro Biotech (NASDAQ:ADRO) Stock To a

Aduro BioTech Inc is a United States clinical-stage immunotherapy company. The company has a market cap of $1.89 billion. The Firm has developed or acquired technology platforms designed to activate potent and lasting immune responses against cancer: live, attenuated Listeria, GVAX and cyclic dinucleotides . It currently has negative earnings. Aduro’s lead program is an immunotherapy regimen combining Listeria CRS-207 and GVAX Pancreas in patients with metastatic pancreatic cancer who have failed at least one therapy.

According to Zacks Investment Research, “Aduro Biotech, Inc. is an immunotherapy company. The Company develops technology and vaccines for the treatment of cancer and mesothelin-expressing tumors. Its product pipeline includes CRS-207, ADU-623, ADU-214, ADU-741, CDN and STINGVAX which are in different clinical trial. Aduro Biotech, Inc. is based in BERKELEY, United States.” Get a free copy of the Zacks research report on Aduro BioTech Inc (ADRO)

COMMENTS: